ReViral Information

View Top Employees from ReViral

ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.

Website	http://www.reviral.co.uk
Revenue	$11.8 million
Employees	5 (1 on RocketReach)
Founded	2011
Phone	+44 29 2078 1795
Industry	Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Medical, Health Care, Therapeutics
Web Rank	6 Million
Keywords	Viral Diseases, Antiviral Drugs, Respiratory Infections, Antiviral Research, Novel Therapeutics, Innovative Treatments, Respiratory Health, First-In-Class Drugs, Biotechnology, Emerging Biotech, Health Technology, Pharmaceutical, New Medicines, Drug Development, Clinical Trials
Competitors	Moderna Therapeutics, アステラス製薬（株）, Emergent BioSolutions, Novavax, Halozyme, Inc., CureVac, INOVIO Pharmaceuticals, Inc., Vaxart, Inc., VBI Vaccines Inc., Bio-Matrix Scientific Group Inc +32 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies